Observational Study of iv Ibandronate in Women With Postmenopausal Osteoporosis

• Status: Completed
• Trial end date: 2014-04-01
• Target enrollment: 0
• Participant gender: Female

Summary

This observational study assess the safety of intravenous Ibandronate (Bonviva) intermittent administration in patients with postmenopausal osteoporosis and the efficacy of IV Ibandronate (Bonviva treatment through relative lumbar spine and hip bone mineral densitometry form baseline at year 1)

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Clinic of Endocrinology and Metabolic Disorders, Macedonia
• Collaborators: Clinic for Orthopedic Surgery, Skopje; General Hospital, Kumanovo; General Hospital, Struga; Medical Faculty, Institute for Epidemiology and Biostatistics, Skopje
• Treatments: Ibandronic Acid

Criteria

Inclusion Criteria:

• Patients had post menopausal osteoporosis

• Patients had no contraindication for bisphosphonates

• Patients had been naive for ibandronate therapy

• Patients who have signed informed consent and are willing to share their data for data analysis

Exclusion Criteria:

• Is not Ibandronate naïve

• Hypersensitivity to any component of the bisphosphonates Ibandronate;

• Administration of any investigational drug within 30 days preceding the first dose of the study drug.